Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  European journal of medicinal chemistry

• Publication date

  2018-02-10

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejmech.2018.01.007PMID 29335209
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease.

  2017cited by this paper
• Update on Alzheimer's and the Dementias: Introduction.

  2017cited by this paper
• Therapies for Prevention and Treatment of Alzheimer's Disease

  2016cited by this paper
• Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer's Disease.

  2016cited by this paper
• Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer's disease based on the fusion of donepezil and melatonin.

  2016cited by this paper
• A review on Alzheimer’s disease pathophysiology and its management: an update

  2015cited by this paper
• UniProt: A hub for protein information

  2015cited by this paper
• Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment.

  2015cited by this paper
• N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor.

  2014cited by this paper
• 2013 Alzheimer's disease facts and figures

  2013cited by this paper
• Molecular recognition of rosmarinic acid from Salvia sclareoides extracts by acetylcholinesterase: a new binding site detected by NMR spectroscopy.

  2013cited by this paper
• Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer's drugs targeting acetyl- and butyryl-cholinesterase.

  2013cited by this paper
• Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments

  2013cited by this paper
• Highly selective inhibition of butyrylcholinesterase by a novel melatonin–tacrine heterodimers

  2012cited by this paper
• Structures of human acetylcholinesterase in complex with pharmacologically important ligands.

  2012cited by this paper
• Proteolytic processing of Alzheimer’s β‐amyloid precursor protein

  2012cited by this paper
• Catalytic chameleon dendrimers.

  2011cited by this paper
• AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

  2009cited by this paper
• Potent β-Amyloid Modulators

  2008cited by this paper
• Amyloid–cholinesterase interactions

  2008cited by this paper
• Clustal W and Clustal X version 2.0

  2007cited by this paper
• Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors.

  2006cited by this paper
• Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent

  2005cited by this paper
• Integrated Modeling Program, Applied Chemical Theory (IMPACT)

  2005cited by this paper
• Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.

  2005cited by this paper
• Estimating Human Oral Fraction Dose Absorbed: A Correlation Using Rat Intestinal Membrane Permeability for Passive and Carrier-Mediated Compounds

  2004cited by this paper
• Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery.

  2004cited by this paper
• Competition STD NMR for the detection of high‐affinity ligands and NMR‐based screening

  2004cited by this paper
• NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors.

  2003cited by this paper
• Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.

  2003cited by this paper
• High throughput artificial membrane permeability assay for blood-brain barrier.

  2003cited by this paper
• A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential.

  2002cited by this paper
• Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine.

  2002cited by this paper
• Predicting blood-brain barrier permeation from three-dimensional molecular structure.

  2000cited by this paper
• Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function

  1998cited by this paper
• Recombinant human butyrylcholinesterase G390V, the fluoride-2 variant, expressed in Chinese hamster ovary cells, is a low affinity variant.

  1993cited by this paper
• Send Orders of Reprints at Reprints@benthamscience.net Acetylcholinesterase Inhibitors: Pharmacology and Toxicology

  year unknowncited by this paper

• N-substituted thiourea derivatives based aminoalcohols: Discovery of potent cholinesterase inhibitors as new therapeutic approach In Alzheimer’s disease

  2026cites this paper
• Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024

  2025cites this paper
• Indole-Based Compounds in the Development of Anti-Neurodegenerative Agents

  2024cites this paper
• Synthesis and biological evaluation of substituted acetamide derivatives as potential butyrylcholinestrase inhibitors

  2023cites this paper
• Piperidine Derivatives: Recent Advances in Synthesis and Pharmacological Applications

  2023influential citation
• Exploiting butyrylcholinesterase inhibitors through a combined 3-D pharmacophore modeling, QSAR, molecular docking, and molecular dynamics investigation

  2023cites this paper
• Molecular chameleons in drug discovery

  2023cites this paper
• Advances in screening assays for identifying cholinesterase ligands

  2023cites this paper
• From tryptophan-based amides to tertiary amines: Optimization of a butyrylcholinesterase inhibitor series.

  2022cites this paper
• Design, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease.

  2022cites this paper
• Recent developments of synthesis and biological activity of sultone scaffolds in medicinal chemistry

  2021cites this paper
• The structure-based optimization of δ-sultone-fused pyrazoles as selective BuChE inhibitors.

  2020cites this paper
• Advanced analytical methodologies in Alzheimer's disease drug discovery.

  2020cites this paper
• Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors.

  2019cites this paper
• Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool.

  2019cites this paper
• Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease.

  2019cites this paper
• Theoretical and Experimental Approaches Aimed at Drug Design Targeting Neurodegenerative Diseases

  2019cites this paper
• Discovery of δ-sultone-fused pyrazoles for treating Alzheimer's disease: Design, synthesis, biological evaluation and SAR studies.

  2019cites this paper
• Overview of novel multifunctional agents based on conjugates of γ-carbolines, carbazoles, tetrahydrocarbazoles, phenothiazines, and aminoadamantanes for treatment of Alzheimer's disease.

  2019cites this paper
• Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease.

  2018cites this paper
• RECENT UPDATES IN CHEMISTRY OF ALZHEIMER'S SYNTHETIC MOLECULES: A NOVEL INSIGHT INTO THE DRUG DISCOVERY

  year unknowncites this paper